Comparison of recombinant granulocyte colony-stimulating factor, recombinant human granulocyte-macrophage colony-stimulating factor and placebo for treatment of septic preterm infants

Division of Neonatology, Department of Pediatrics, Weill Medical College of Cornell University, New York City, NY, USA.
The Pediatric Infectious Disease Journal (Impact Factor: 2.72). 12/2002; 21(11):1061-5. DOI: 10.1097/01.inf.0000036091.75362.b9
Source: PubMed


To reduce morbidity and mortality adjuvant cytokine therapy was administered to septic neonates with variable results. The objective of this case series was to compare the effectiveness of recombinant human granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) and recombinant granulocyte colony-stimulating factor (rG-CSF) with that of placebo in correcting neutropenia induced by sepsis.
Symptomatic, septic premature neonates with or without a positive blood culture were eligible. Twenty-eight patients were randomized: 10 received rG-CSF (5 microg/kg/dose i.v. twice a day); 10 received rhuGM-CSF (4 microg/kg/dose i.v. twice a day) and 8 received placebo for a maximum of 7 days, or until an absolute neutrophil count (ANC) of 10,000 cells/mm was reached.
A significant increase in the ANC above the baseline was present on Day 2 in the rG-CSF group (P = 0.015) and on Day 5 in the rhuGM-CSF (P = 0.002) and placebo (P = 0.027) groups. The ANC of the rG-CSF group was significantly above that in the rhuGM-CSF and placebo groups on Day 7 (P = 0.03). Mortality and neonatal intensive care unit morbidity was not significantly different between the groups.
The neutrophil count in the rG-CSF-treated group increased significantly faster than that in the placebo or rhuGM-CSF group.

5 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The strict definition of passive immunoprophylaxis includes the administration of exogenously produced antibodies (polyclonal and monoclonal) to prevent infections in exposed individuals, inactivate bacterial toxins or "correct" hypogammaglobulinemia in immunocompromised hosts. This definition can be broadened to include modulators of the immune system. Despite advances in chemotherapy and vaccine development, suitable treatment is not currently available for many pathogens. As a result, passive immunization is an appropriate therapeutic option for many organisms.
    Current Opinion in Pharmacology 11/2003; 3(5):486-96. DOI:10.1016/j.coph.2003.05.005 · 4.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent steps to prevent neonatal sepsis due to group B Streptococcal infection have lowered the attack rate from this organism, but may not have lowered overall sepsis rates. Mortality from sepsis stills remains between 20 and 40% and is probably so high due to the immunological immaturity of the newborn. Although antibiotics remain the mainstay for treatment, adjunctive therapies aimed at improving the immunological integrity of the neonatal patient have a role in treatment and may improve outcomes. We discuss several adjunctive therapies, along with the physiologic rationale for their use, and discuss an approach for their inclusion in therapy for neonatal sepsis.
    Newborn and Infant Nursing Reviews 03/2004; 4(1):46-50. DOI:10.1053/j.nainr.2003.09.003
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Many previously widely accepted neonatal transfusion practices are changing as neonatologists become more aware of the risks to their patients of multiple blood product transfusions. Recent literature and research on neonatal transfusion practice are here reviewed, and practical guidelines and trigger thresholds for blood products commonly used in neonatal medicine are proposed.
    Archives of Disease in Childhood - Fetal and Neonatal Edition 03/2004; 89(2):101F-107. DOI:10.1136/adc.2002.019760 · 3.12 Impact Factor
Show more